Vedam-Mai Vinata, Deisseroth Karl, Giordano James, Lazaro-Munoz Gabriel, Chiong Winston, Suthana Nanthia, Langevin Jean-Philippe, Gill Jay, Goodman Wayne, Provenza Nicole R, Halpern Casey H, Shivacharan Rajat S, Cunningham Tricia N, Sheth Sameer A, Pouratian Nader, Scangos Katherine W, Mayberg Helen S, Horn Andreas, Johnson Kara A, Butson Christopher R, Gilron Ro'ee, de Hemptinne Coralie, Wilt Robert, Yaroshinsky Maria, Little Simon, Starr Philip, Worrell Greg, Shirvalkar Prasad, Chang Edward, Volkmann Jens, Muthuraman Muthuraman, Groppa Sergiu, Kühn Andrea A, Li Luming, Johnson Matthew, Otto Kevin J, Raike Robert, Goetz Steve, Wu Chengyuan, Silburn Peter, Cheeran Binith, Pathak Yagna J, Malekmohammadi Mahsa, Gunduz Aysegul, Wong Joshua K, Cernera Stephanie, Hu Wei, Wagle Shukla Aparna, Ramirez-Zamora Adolfo, Deeb Wissam, Patterson Addie, Foote Kelly D, Okun Michael S
Norman Fixel Institute for Neurological Diseases and the Program for Movement Disorders and Neurorestoration, Department of Neurology, University of Florida, Gainesville, FL, United States.
Department of Bioengineering, Stanford University, Stanford, CA, United States.
Front Hum Neurosci. 2021 Apr 19;15:644593. doi: 10.3389/fnhum.2021.644593. eCollection 2021.
We estimate that 208,000 deep brain stimulation (DBS) devices have been implanted to address neurological and neuropsychiatric disorders worldwide. DBS Think Tank presenters pooled data and determined that DBS expanded in its scope and has been applied to multiple brain disorders in an effort to modulate neural circuitry. The DBS Think Tank was founded in 2012 providing a space where clinicians, engineers, researchers from industry and academia discuss current and emerging DBS technologies and logistical and ethical issues facing the field. The emphasis is on cutting edge research and collaboration aimed to advance the DBS field. The Eighth Annual DBS Think Tank was held virtually on September 1 and 2, 2020 (Zoom Video Communications) due to restrictions related to the COVID-19 pandemic. The meeting focused on advances in: (1) optogenetics as a tool for comprehending neurobiology of diseases and on optogenetically-inspired DBS, (2) cutting edge of emerging DBS technologies, (3) ethical issues affecting DBS research and access to care, (4) neuromodulatory approaches for depression, (5) advancing novel hardware, software and imaging methodologies, (6) use of neurophysiological signals in adaptive neurostimulation, and (7) use of more advanced technologies to improve DBS clinical outcomes. There were 178 attendees who participated in a DBS Think Tank survey, which revealed the expansion of DBS into several indications such as obesity, post-traumatic stress disorder, addiction and Alzheimer's disease. This proceedings summarizes the advances discussed at the Eighth Annual DBS Think Tank.
我们估计，全球已植入20.8万台深部脑刺激（DBS）设备，用于治疗神经和神经精神疾病。DBS智库的演讲者汇总数据后确定，DBS的应用范围不断扩大，已被应用于多种脑部疾病，以调节神经回路。DBS智库成立于2012年，为临床医生、工程师以及来自行业和学术界的研究人员提供了一个空间，他们可以在此讨论当前和新兴的DBS技术以及该领域面临的后勤和伦理问题。重点是旨在推动DBS领域发展的前沿研究与合作。由于与2019冠状病毒病疫情相关的限制，第八届年度DBS智库会议于2020年9月1日和2日以线上方式（Zoom视频通信）举行。会议聚焦于以下方面的进展：（1）光遗传学作为理解疾病神经生物学的工具以及受光遗传学启发的DBS；（2）新兴DBS技术的前沿进展；（3）影响DBS研究和医疗服务获取的伦理问题；（4）抑郁症的神经调节方法；（5）推进新型硬件、软件和成像方法；（6）在自适应神经刺激中使用神经生理信号；（7）使用更先进的技术改善DBS临床疗效。有178名与会者参与了DBS智库调查，该调查显示DBS已扩展到肥胖症、创伤后应激障碍、成瘾和阿尔茨海默病等多种适应症。本论文集总结了第八届年度DBS智库会议上讨论的进展。
